John S. Beck
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John S. Beck has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Scott E. Counts
Department of Translational Neuroscience Michigan State University College of Human Medicine Grand Rapids Michigan USA
2 shared publications Anne M. Dorrance
Michigan State University
1 shared publication- Anumantha G. Kanthasamy
Department of Biomedical Sciences, Iowa State University, Ames, IA 50011, USA
1 shared publication - Catherine Kudela
Department of Physiology and Pharmacology, College of Veterinary Medicine University of Georgia Athens Georgia USA
1 shared publication Chunqi Qian
Michigan State University
1 shared publication- Gargi Khadse
Isakson Center for Neurological Disease Research University of Georgia Athens Georgia USA
1 shared publication
Latest Publications
- 16 October 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Locus coeruleus degeneration impairs forebrain arteriole physiology and perfusion in a rat model of Alzheimer's disease
The locus coeruleus (LC) provides forebrain norepinephrine (NE) and degenerates early in Alzheimer's disease (AD). We have shown that experimental LC lesions in the Tg344-19 AD rat model result in parenchymal arteriole (PA) stenosis, blood-brain barrier permeability, amyloid angiopathy, and cognitive impairment. Here, we show that PAs from LC-lesioned Tg344-19 AD rats displayed increased myogenic tone and decreased responsiveness to TRPV4 channel agonists, which was reversible by NE replacement. MRI studies indicated reduced forebrain perfusion and fractional anisotropy in LC-lesioned animals compared to controls. Targeting LC-mediated effects on cerebral hemodynamics presents a compelling AD therapeutic target.
- 16 October 2026
- Published by SAGE Publications in Journal of Alzheimer’s Disease
Locus coeruleus degeneration impairs forebrain arteriole physiology and perfusion in a rat model of Alzheimer's disease
The locus coeruleus (LC) provides forebrain norepinephrine (NE) and degenerates early in Alzheimer's disease (AD). We have shown that experimental LC lesions in the Tg344-19 AD rat model result in parenchymal arteriole (PA) stenosis, blood-brain barrier permeability, amyloid angiopathy, and cognitive impairment. Here, we show that PAs from LC-lesioned Tg344-19 AD rats displayed increased myogenic tone and decreased responsiveness to TRPV4 channel agonists, which was reversible by NE replacement. MRI studies indicated reduced forebrain perfusion and fractional anisotropy in LC-lesioned animals compared to controls. Targeting LC-mediated effects on cerebral hemodynamics presents a compelling AD therapeutic target.
- Open Access
- 18 September 2026
- Published by Wiley in British Journal of Pharmacology
Bioengineered microbiotic levodopa therapy improves cognition and reduces pathology in a rat model of Alzheimer's disease
Background and Purpose: Degeneration of the pontine noradrenergic and midbrain dopaminergic systems contributes to cognitive‐behavioural disturbances during the prodromal stages of Alzheimer's disease (AD). We developed a genetically engineered, programmable probiotic Escherichia coli Nissle 1917 strain (EcN rha L‐DOPA ) capable of producing L‐3,4‐dihydroxyphenylalanine (L‐DOPA) in a sustained and titratable manner, thus offering a novel gut‐brain delivery mechanism to increase brain levels of noradrenaline and dopamine during the early stages of AD. Experimental Approach: We replicated locus coeruleus (LC) projection system degeneration in AD by administering dopamine‐ β ‐hydroxylase IgG‐saporin immunotoxin into the prefrontal cortex of 6‐months‐old Tg344‐19 AD rats. The animals then received EcN rha L‐DOPA /benserazide or placebo by daily gavage for 6 weeks. We assessed cognitive‐behavioural function prior to postmortem assessments of amyloid‐β plaque load, glial cell activation and neuronal and synaptic markers. Gut colonization, along with plasma and brain L‐DOPA, dopamine, noradrenaline and metabolite levels, were also measured. Key Results: EcN rha L‐DOPA displayed stable gut colonization and resulted in sustained therapeutic levels of L‐DOPA in plasma and brain, resulting in increased cortical and hippocampal noradrenaline levels. EcN rha L‐DOPA reduced anxiety‐like behaviour improved spatial and working memory. The treatment reduced forebrain A β plaque and MHC‐II antigen‐presenting microglial load. Additionally, EcN rha L‐DOPA increased protein levels of the dendritic spine marker PSD95. Conclusions and Implications: This translational study suggests that EcN rha L‐DOPA modifies AD by boosting brain catecholamine production, reducing A β accumulation and neuroinflammation, promoting synaptic health, and enhancing cognitive function. Collectively, these results highlight EcN rha L‐DOPA as a promising preclinical engineered gut microbiome‐based therapeutic strategy for early‐stage AD.
- 18 September 2026
- Published by Wiley in British Journal of Pharmacology
Open AccessBioengineered microbiotic levodopa therapy improves cognition and reduces pathology in a rat model of Alzheimer's disease
Background and Purpose: Degeneration of the pontine noradrenergic and midbrain dopaminergic systems contributes to cognitive‐behavioural disturbances during the prodromal stages of Alzheimer's disease (AD). We developed a genetically engineered, programmable probiotic Escherichia coli Nissle 1917 strain (EcN rha L‐DOPA ) capable of producing L‐3,4‐dihydroxyphenylalanine (L‐DOPA) in a sustained and titratable manner, thus offering a novel gut‐brain delivery mechanism to increase brain levels of noradrenaline and dopamine during the early stages of AD. Experimental Approach: We replicated locus coeruleus (LC) projection system degeneration in AD by administering dopamine‐ β ‐hydroxylase IgG‐saporin immunotoxin into the prefrontal cortex of 6‐months‐old Tg344‐19 AD rats. The animals then received EcN rha L‐DOPA /benserazide or placebo by daily gavage for 6 weeks. We assessed cognitive‐behavioural function prior to postmortem assessments of amyloid‐β plaque load, glial cell activation and neuronal and synaptic markers. Gut colonization, along with plasma and brain L‐DOPA, dopamine, noradrenaline and metabolite levels, were also measured. Key Results: EcN rha L‐DOPA displayed stable gut colonization and resulted in sustained therapeutic levels of L‐DOPA in plasma and brain, resulting in increased cortical and hippocampal noradrenaline levels. EcN rha L‐DOPA reduced anxiety‐like behaviour improved spatial and working memory. The treatment reduced forebrain A β plaque and MHC‐II antigen‐presenting microglial load. Additionally, EcN rha L‐DOPA increased protein levels of the dendritic spine marker PSD95. Conclusions and Implications: This translational study suggests that EcN rha L‐DOPA modifies AD by boosting brain catecholamine production, reducing A β accumulation and neuroinflammation, promoting synaptic health, and enhancing cognitive function. Collectively, these results highlight EcN rha L‐DOPA as a promising preclinical engineered gut microbiome‐based therapeutic strategy for early‐stage AD.